Michael Guice, MD
General Practice · Los Angeles, CANPI 1215944285
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 35.9% of the total. Reporting peaked in 2019 at $118 and has fallen 77.1% since, to $27 in 2025. That places this record below the midpoint for general practice clinicians in CA, where the typical reported total is $211.
Across 12 payments — averaging $21.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$92
- Sanofi-aventis U.S. LLC$75
- Amgen$47
- Bayer$24
- Novo Nordisk$19
Across 18 payments — averaging $2927.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$51K
- Amarin Pharma, Inc.$2K
- GSK$500
- Merck$171
What the payments were for
- Food & beverage$256100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $92 |
| Sanofi-aventis U.S. LLC | 4 | $75 |
| Amgen | 2 | $47 |
| Bayer | 1 | $24 |
| Novo Nordisk | 1 | $19 |
How this compares
$256 in reported general payments places this provider in the 50th percentile of 12,963 general practice providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 77 | $94,673 |
| EliquisApixaban | 14 | $17,348 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $16,504 |
| JanuviaSitagliptin Phosphate | 12 | $13,866 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 37 | $11,113 |
| ZenpepLipase/Protease/Amylase | 13 | $10,899 |
| Nifedipine ErNifedipine | 103 | $3,462 |
| Celecoxib | 65 | $2,947 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 53 | $2,131 |
| Potassium Chloride | 88 | $1,652 |
| Labetalol Hcl | 47 | $1,618 |
| Metformin Hcl | 101 | $1,146 |
| Gabapentin | 76 | $1,075 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 33 | $936 |
| Levothyroxine Sodium | 54 | $926 |
Paid to pharmacies, not to this prescriber.
Other general practice in Los Angeles
- Abdi SameniLos Angeles$316K
- Kent HwangLos Angeles$290K
- Kyle StanleyLos Angeles$259K
- Richard KimLos Angeles$97K
- Michael SchneiderLos Angeles$53K
- Ronald JeffersonLos Angeles$45K
- Nathan LiLancaster$5.2M
- Milton McCollSan Jose$4.9M
- Frederic MollRedwood City$2.5M
- Bradley ChingUpland$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.